Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02536794 · ClinicalTrials.gov registry record · Phase 2

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

A Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, sponsored by Northwestern University.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
2
Study locations

NCT02536794 is a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma that has completed, run by Northwestern University. The registered enrollment target is 30 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02536794, a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The main purpose of this study is to determine the anti-tumor activity of MEDI4736 in combination with tremelimumab in patients with metastatic HER2-negative breast cancer. Both MEDI4736 and tremelimumab are antibodies (proteins used by the immune system to fight infections and cancers). MEDI4736 attaches to a protein in tumors called PD-L1. It may prevent cancer growth by helping certain blood cells of the immune system get rid of the tumor. Tremelimumab stimulates (wakes up) the immune system to attack the tumor by inhibiting a protein molecule called CTLA-4 on immune cells. Combining the actions of these drugs may result in better treatment options for patients with breast cancer.

Conditions Studied

Stage IV Breast Cancer Recurrent Breast Carcinoma HER2/Neu Negative Estrogen Receptor Negative Estrogen Receptor Positive

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Tremelimumab
  • OTHER Pharmacological Study
  • BIOLOGICAL Anti-B7H1 Monoclonal Antibody MEDI4736

Study Locations (2)

Illinois

  • Northwestern University - Chicago
  • Northwestern University- Lake Forest Hospital - Lake Forest

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-01-14
Est. Completion 2021-01-22
Phase Phase 2

Sponsor

Northwestern University

1,209 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02536794

The ClinicalTrials.gov registry entry for NCT02536794 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02536794 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT02536794 about?

NCT02536794 is a clinical study titled "MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer". The main purpose of this study is to determine the anti-tumor activity of MEDI4736 in combination with tremelimumab in patients with metastatic HER2-negative breast cancer. Both MEDI4736 and tremelimumab are antibodies (proteins used by the immune system to fight infections and cancers). MEDI4736 at...

What is the current status of trial NCT02536794?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-01-14. Estimated completion is 2021-01-22.

What conditions does trial NCT02536794 study?

This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Carcinoma, HER2/Neu Negative, Estrogen Receptor Negative, Estrogen Receptor Positive.

What interventions are being tested in trial NCT02536794?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tremelimumab (BIOLOGICAL), Pharmacological Study (OTHER), Anti-B7H1 Monoclonal Antibody MEDI4736 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02536794?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02536794 being conducted?

This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Breast Cancer

All registered trials for this condition

Recurrent Breast Carcinoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.